Technology Brief -- Repligen Corp.:
   Concern Creates Partnership
   To Test and Develop Drug
Repligen said rPF4 has shown promise in preventing the
formation of blood vessels that accompany and promote tumor
growth. The company plans first to test the drug to treat
acquired immune deficiency syndrome patients who have
Kaposi's sarcoma, a kind of skin cancer, and brain tumor
patients.